Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RARE
  • CUSIP: N/A
  • Web: www.ultragenyx.com
  • Market Cap: $2.18703 billion
  • Outstanding Shares: 42,458,000
Average Prices:
  • 50 Day Moving Avg: $53.31
  • 200 Day Moving Avg: $59.14
  • 52 Week Range: $49.56 - $91.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.55
  • P/E Growth: -0.24
Sales & Book Value:
  • Annual Revenue: $115,999.00
  • Price / Sales: 18,853.71
  • Book Value: $10.12 per share
  • Price / Book: 5.09
  • EBITDA: ($280,320,000.00)
  • Return on Equity: -60.04%
  • Return on Assets: -52.85%
  • Current Ratio: 6.70%
  • Quick Ratio: 6.70%
  • Average Volume: 310,775 shs.
  • Beta: 1.88
  • Short Ratio: 21.74

Frequently Asked Questions for Ultragenyx Pharmaceutical (NASDAQ:RARE)

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Thursday, July, 27th. The company reported ($1.72) EPS for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same period in the previous year, the business posted ($1.46) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

When will Ultragenyx Pharmaceutical make its next earnings announcement?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Ultragenyx Pharmaceutical.

Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?

17 analysts have issued 1-year target prices for Ultragenyx Pharmaceutical's shares. Their predictions range from $55.00 to $90.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $71.94 in the next twelve months. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (7/18/2017)
  • 2. Cowen and Company analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)
  • 3. Canaccord Genuity analysts commented, "INSM’s Ph3 Arikayce NTM CONVERT trial data is due ~September of this year." (5/8/2017)
  • 4. Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)

Who are some of Ultragenyx Pharmaceutical's key competitors?

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board
  • Emil D. Kakkis M.D. Ph.D., President, Chief Executive Officer, Director
  • Shalini Sharp, Chief Financial Officer, Executive Vice President
  • Sunil Agarwal M.D., President - Research and Development
  • Karah Parschauer, Executive Vice President, General Counsel
  • Jayson Dallas M.D., Chief Commercial Officer and Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer, Executive Vice President
  • Thomas Kassberg, Chief Business Officer, Executive Vice President
  • John R. Pinion II, Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research
  • William E. Aliski, Independent Director

Who owns Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.94%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Who sold Ultragenyx Pharmaceutical stock? Who is selling Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Rockefeller Financial Services Inc.. Company insiders that have sold Ultragenyx Pharmaceutical stock in the last year include Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy Ultragenyx Pharmaceutical stock?

Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $51.51.

MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  435 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  586
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $71.94 (39.66% upside)
Consensus Price Target History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Price Target History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Morgan StanleyReiterated RatingEqual Weight$69.00 -> $71.00N/AView Rating Details
9/19/2017Robert W. BairdReiterated RatingBuyLowView Rating Details
9/14/2017WedbushUpgradeNeutral -> Outperform$62.00HighView Rating Details
9/12/2017Canaccord GenuityReiterated RatingBuyLowView Rating Details
9/6/2017Barclays PLCInitiated CoverageEqual Weight$60.00HighView Rating Details
8/23/2017Jefferies Group LLCSet Price TargetHold$62.00LowView Rating Details
8/23/2017J P Morgan Chase & CoSet Price TargetBuy$87.00 -> $76.00LowView Rating Details
8/23/2017JMP SecuritiesLower Price TargetMarket Outperform$90.00 -> $80.00LowView Rating Details
8/23/2017Stifel NicolausReiterated RatingBuy$95.00 -> $85.00HighView Rating Details
8/23/2017Leerink SwannReiterated RatingOutperform$89.00 -> $83.00HighView Rating Details
8/23/2017Cowen and CompanyReiterated RatingOutperformHighView Rating Details
8/23/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$105.00 -> $55.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$63.00HighView Rating Details
8/8/2017HC WainwrightReiterated RatingNeutral -> Neutral$72.00 -> $75.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00HighView Rating Details
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> NeutralHighView Rating Details
11/30/2016Citigroup Inc.DowngradeNeutral -> SellN/AView Rating Details
9/14/2016Credit Suisse GroupReiterated RatingBuy$101.00N/AView Rating Details
6/28/2016Bank of America CorporationInitiated CoverageBuy$72.00N/AView Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Earnings History by Quarter for Ultragenyx Pharmaceutical (NASDAQ RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($1.80)N/AView Earnings Details
7/27/2017Q2 2017($1.73)($1.72)$0.01 millionViewN/AView Earnings Details
5/4/2017Q1 2017($1.71)($1.63)$0.05 millionViewListenView Earnings Details
2/16/2017Q4 2016($1.72)($1.75)$0.05 million$0.01 millionViewN/AView Earnings Details
11/7/2016Q3($1.53)($1.64)$7.60 million$0.11 millionViewListenView Earnings Details
8/8/2016Q2($1.44)($1.46)$0.02 millionViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
2017 EPS Consensus Estimate: ($7.23)
2018 EPS Consensus Estimate: ($5.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.82)($1.69)($1.75)
Q2 20174($1.93)($1.59)($1.76)
Q3 20174($2.01)($1.62)($1.85)
Q4 20174($2.09)($1.67)($1.87)
Q1 20181($1.87)($1.87)($1.87)
Q2 20181($0.52)($0.52)($0.52)
Q3 20181($1.78)($1.78)($1.78)
Q4 20181($1.78)($1.78)($1.78)
(Data provided by Zacks Investment Research)


Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 96.07%
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/28/2017Emil D KakkisCEOBuy7,500$52.52$393,900.00View SEC Filing  
5/26/2017Theodore Alan HuizengaVPSell480$57.46$27,580.80View SEC Filing  
3/9/2017Theodore Alan HuizengaInsiderSell2,500$86.34$215,850.00View SEC Filing  
3/2/2017Shalini SharpCFOSell12,000$90.10$1,081,200.00View SEC Filing  
2/27/2017Shalini SharpCFOSell12,000$80.14$961,680.00View SEC Filing  
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.00View SEC Filing  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.00View SEC Filing  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.00View SEC Filing  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00View SEC Filing  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Loading headlines, please wait.



Ultragenyx Pharmaceutical (RARE) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.